information

Whoever comes in this website may find a hint

Phage therapy is influenced by:

Phage therapy is influenced by:

Country :
the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view

From Wikipedia


If the target host* of a phage therapy treatment is not
an animal the term "
biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

"In silico"

From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Wednesday 21 October 2015

Encapsulated bacteriophages for enhanced oral phage therapy



Link

This research found that nanoencapsulation confers to bacteriophages a greater resistance to the effects of the stomach low pH while also increasing their residence time in the intestinal tract.

Tuesday 13 October 2015

News from PhagoBurn

old post
  • Participation to the ICAAC-ICC 2015 Meeting - September 18th, 2015
Gregory Resch (CHUV) took part in the ICAAC-ICC Meeting which was held in San Diego (CA, United States). He gave a talk entitled "Phage-based Therapies", with a specific focus on Phagoburn.


here

  • Participation to the 16th Congress of the European Burn Association - September 18th, 2015
Jean-Paul Pirnay (Queen Astrid) gave a talk during the annual congress of the EBA, which took place in Hannover, Germany in September 2015. He presented PhagoBurn and specifically the launching of the clinical study.


here 

  • Participation to Evergreen Conference - August 2-7th, 2015
Jérôme Gabard (Pherecydes) took part in the 21st Biennial Evergreen International Phage Meeting which was held in Evergreen (WA, United States). During this event, he presented the progress of Phagoburn project since the previous Meeting.

here


  • Participation to NIH Conference - July 20th, 2015
Patrick Jault (HIA Percy) gave a talk during a NIH Meeting which took place in Rockville (United States), in July. This talk specifically presented PhagoBurn and the launching of the clinical trial.

here 
  • Participation to Bacteriophages 2015 - January 27-29th, 2015
Gilbert Verbeken (Queen Astrid) gave a talk entitled "European Implementation of Bacteriophage Therapy: Impact of Medicinal Product Legislation on Tailored Hospital Care" during the Bacteriophages 2015 event, held in London (UK) in January. 


  here